INTRODUCTION
The ability to disrupt and/or manipulate selected genes in embryonic stem (ES) cells and whole animals has revolutionized the study of molecular and developmental biology. However, primary tissue from gene-targeted mice has limited applications because of the relatively small amount of material available, heterogeneity of cell types present, variability due to harvests from multiple animals, and cumbersome nature of accessing material for repeated experiments. Generation of immortalized cell lines from in vitro differentiated gene-targeted ES cells or primary cells from gene-targeted animals allows for a uniform, self-sustaining source of material for repeated studies.
Several different approaches have been reported for the immortalization of primary murine hematopoietic cells that include retroviral expression of Myc (Green et al., 1989) , Myb (Gonda et al., 1989) , Hoxb8 (Hox-2.4; Perkins and Cory, 1993) , TLX1 (formerly called HOX11; Hawley et al., 1994a) , E2A-Pbx1 (Kamps and Wright, 1994) , MLL (Lavau et al., 1997) , Lhx2 (Pinto do et al., 2002) , RARA (Du et al., 1999) , Hoxa9 (Calvo et al., 2000; Schnabel et al., 2000) , Notch1 (Varnum-Finney et al., 2000) , v-raf/v-myc (Coghill et al., 2001) , MYST3-NCOA2 (Deguchi et al., 2003) , Evi1 (Du et al., 2005) , HOXB6 (Fischbach et al., 2005) , HOXB4 (Zhang et al., 2007) , β-catenin (Templin et al., 2008) , and Id1 (Suh et al., 2008) . A subset of the genes utilized in these studies-most notably, TLX1-have also been demonstrated to efficiently immortalize ES cell-derived hematopoietic cells (Keller et al., 1998; Cantor et al., 2002; Shaw et al., 2006; Riz et al., 2007) .
TLX1 IMMORTALIZATION OF ES CELL IN VITRO DIFFERENTIATED HEMATOPOIETIC PROGENITORS
This protocol involves in vitro differentiation of murine ES cells to embryoid bodies (EBs) under conditions that promote hematopoietic development. The EBs (containing hematopoietic progenitor cells) are then disaggregated and the released cells transduced with TLX1-expressing retroviruses by coculture with TLX1 retroviral producer cells to generate immortalized hematopoietic cells. Single cell clones are then isolated to produce cell lines.
Materials
Murine ES cells, gel-adapted (grown on gelatinized plates, not on feeder cells) and of low passage number (see UNIT 1C.4) IMDM-ES-15 with MTG, LIF, and pen/strep (see recipe) 0.05% (w/v) and 0.25% (w/v) trypsin/EDTA (Invitrogen, cat. no. 25200 and 25300, respectively) IMDM-ES-5 with MTG and pen/strep (see recipe) Primary ES cell differentiation medium (see recipe) TLX1-retroviral producer cell line (see Support Protocol):
GP+E-86/MSCV-HOX11 for cotransduction of the neomycin phosphotransferase (neo) gene conferring resistance to the neomycin analog Geneticin in mammalian cells or GP+E-86/MSCVhyg-HOX11 for cotransduction of the hygromycin B phosphotransferase (hyg) drug resistance gene Isocove's modified Dulbecco's medium (IMDM; Invitrogen, cat. no. 12440) IMDM-ES-15: IMDM supplemented with 15% (v/v) ES-FBS Coculture medium (see recipe)
IMDM-ES-15 with glutamine and pen/strep (see recipe) Immortalized cell medium (see recipe) 50 mg/ml Geneticin (Invitrogen cat. no. 10131-035) or 50 mg/ml hygromycin B (Mediatech) stock Gelatinized 25-cm 2 tissue culture flasks (see recipe) 15-ml and 50-ml conical centrifuge tubes (sterile) Tissue culture centrifuge (refrigerated, benchtop centrifuge with swinging bucket rotor) 100-mm petri dishes 100-mm and 60-mm tissue culture dishes 20-G needle and 3-ml syringe Hemacytometer Cell irradiator (optional) Additional reagents and equipment for counting viable cells (UNIT 1C.3) Prepare ES cells 1. Two days before inducing differentiation, split the murine gel-adapted ES cells at various dilutions (e.g., 1:10, 1:5, 1:3) into 10 ml of IMDM-ES-15 with MTG, LIF, and pen/strep and plate in gelatinized 25-cm 2 flasks. Refeed cells daily.
2. After two days, choose a flask with cells at ∼25% to 50% confluency. Wash cells briefly with 2 ml of 0.05% trypsin/EDTA, and then add 2 ml of 0.25% trypsin/EDTA. Incubate until cells start to loosen from the flask (about 3 min).
3. Pipet up and down several times to dissociate cells and add the suspension to 10 ml of IMDM-ES-15 with MTG, LIF, and pen/strep in a 15-ml centrifuge tube.
4. Centrifuge 5 min at ∼200 × g, 4 • C in a tissue culture centrifuge.
5. Carefully remove the supernatant and resuspend the pellet in 5 ml of IMDM-ES-5 with MTG and pen/strep.
Count the number of viable cells in a hemacytometer (UNIT 1C.3).
Differentiate ES cells to EBs 7. Add 50,000 cells to each of three 100-mm petri dishes (do not use tissue culture dishes) containing 10 ml primary ES differentiation medium. 9. During the EB differentiation, grow TLX1 retroviral producer cells in 100-mm tissue culture dishes, aiming to have cells at ∼90% to 100% confluency on the day of coculture with the ES-derived hematopoietic progenitors (day 6 to 7 of EB differentiation).
Typically, a confluent dish of producer cells split ∼1:7 to 1:10 will be 90% to 100% confluent in ∼3 days.
12. Aspirate supernatant and add 3 ml of 0.25% trypsin/EDTA to the pellet. Incubate 3 min at room temperature.
13. Dissociate embryoid body cells by gentle passage through a 20-G needle six times.
14. Immediately add the suspension to 10 ml of IMDM-ES-15 to neutralize trypsin.
15. Measure the concentration of viable cells using a hemacytometer (UNIT 1C.3).
16. Centrifuge 3 × 10 6 cells 5 min at ∼200 × g, 4 • C, and resuspend in 10 ml coculture medium.
Prepare producer cells 17. Irradiate the TLX1 retroviral producer monolayer with 3 Gy. 18. Wash the irradiated cell monolayer once with 5 ml of IMDM-ES-15 with glutamine and pen/strep.
Immortalize and passage EB cells
19. Gently add the disaggregated EB cell suspension to the irradiated cell monolayer. Incubate the coculture for 3 days without changing the medium. 20. After 3 days, gently agitate the dishes to remove suspension cells loosely adherent to the monolayer and transfer the supernatant to a 15-ml conical tube.
21. Centrifuge 5 min at ∼200 × g, 4 • C.
22. Resuspend the cell pellet in 3 ml immortalized cell medium and incubate in 60-mm tissue culture dish. (Keller et al., 1998; Yu et al., 2002; Riz et al., 2007 (Yu et al., 2002; Su et al., 2006) (Keller et al., 1998; Yu et al., 2002; Riz et al., 2007) . 27. Characterize the clonal lines, depending on the particular application, e.g., by identifying the hematopoietic cell lineages represented, and their relative state of maturation (Support Protocol 4).
ALTERNATE PROTOCOL

TLX1 IMMORTALIZATION OF PRIMARY MURINE HEMATOPOIETIC CELLS
In this protocol, primary hematopoietic cells are harvested from murine fetal liver (FL) or bone marrow (BM) and then cocultured with TLX1-expressing retroviral producer cell lines. After coculture, cells are selected for retroviral expression and cloned to generate immortalized cell lines. Procedures for immortalization of yolk sac-derived precursors cells have also been published (Yu et al., 2002) .
Additional Materials (also see Basic Protocol)
Adult mouse Mouse dissection tools 70% ethanol spray solution 1.5-ml microcentrifuge tubes, sterile 1× PBS, sterile: diluted from 10× phosphate-buffered saline without calcium and magnesium (Sigma, cat. no. P7059) to 1× with water, and sterilized by passing through a 0.22-μm filter 70-μm cell strainer (BD Falcon; optional) 22-G needle and 1-ml syringe (for bone marrow progenitors) 23-G needle and 1-ml syringe (for fetal liver progenitors) 25-G needle and 1-ml syringe (for fetal liver progenitors) NOTE: All protocols using live animals must first be reviewed and approved by an Institutional Animal Care and Use Committee (IACUC) and must follow officially approved procedures for the care and use of laboratory animals.
Prepare TLX1 producer cells
1. Grow TLX1 retroviral producer cell to 90% to 100% confluence in a 100-mm tissue culture dish. Irradiate the cell monolayer with 3 Gy and return to the tissue culture incubator. 
Although irradiation of the producer cell line is recommended, it is not absolutely necessary since the immortalized hematopoietic cells grow in suspension and
Prepare hematopoietic progenitor cells
For bone marrow-derived hematopoietic progenitors 2a. Euthanize an adult mouse by carbon dioxide asphyxiation using compressed gas, or according to institutionally approved methods, and immediately spray the fur over the legs with 70% ethanol to disinfect. Dissect out both femurs and cut off ends.
Methods of euthanasia other than carbon dioxide asphyxiation may be used; however, we do not know if they would affect the cells.
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3a. Hold the cut femur with forceps over a sterile 15-ml conical centrifuge tube and use a 1-ml syringe fitted with a 22-G needle to flush the bone marrow space with 1 ml IMDMES-15 with glutamine and pen/strep (0.5 ml in each direction). Repeat to obtain a total of 2 ml of cell suspension, pooling the sample.
4a. Repeat step 3a, using the other femur, and combine the samples (total 4 ml of cell suspension).
5a. Cap and vortex the tube. Allow debris to settle by gravity at room temperature for 5 min.
6a. Transfer the supernatant to fresh tube and discard the pellet, which contains mostly bone fragments and fibrous debris.
Alternatively, bone marrow fragments and debris can be removed from the flushed marrow by filtering through a sterile 70-μm cell strainer (BD Falcon).
7a. Measure the viable cell concentration using a hemacytometer (UNIT 1C.3).
8a. Centrifuge ∼3 × 10 6 cells 5 min at ∼200 × g, 4 • C, in a tabletop tissue culture centrifuge.
9a. Aspirate and discard the supernatant, and resuspend the cell pellet in 10 ml of coculture medium.
For fetal liver-derived progenitors 2b. Euthanize a pregnant female mouse at embryonic day 13.5 or 14.5 (E13.5 to E14.5) by carbon dioxide asphyxiation using compressed gas, or according to institutionally approved methods.
Methods of euthanasia other than carbon dioxide asphyxiation may be used; however, we do not know if they would affect the cells.
3b. Immediately spray the fur over the abdomen with 70% ethanol. Using forceps and sharp scissors (first soaked in 70% ethanol and wiped dry), incise the abdominal wall and extract the embryos. Place the embryos in a sterile 100-mm petri dish containing sterile 1× PBS, and separate them by cutting with scissors.
4b. Open the yolk sacs and remove the fetuses, keeping them in the 1× PBS. Using blunt dissection with sterile forceps and scissors, remove the fetal livers from the embryos' abdomens.
The liver should come out easily at this stage of development.
5b. Place one fetal liver per sterile 1.5-ml microcentrifuge tube containing 1 ml IMDM-ES-15 with glutamine and pen/strep.
6b. Prepare a single-cell suspension by drawing the tissue through a 23-G needle five times, followed by a 25-G needle five times.
7b. Pool cell suspensions from several fetal livers into a 15-ml conical centrifuge tube. Determine viable cell concentration using a hemacytometer (UNIT 1C.3).
8b. Centrifuge ∼3 × 10 6 cells 5 min at ∼200 × g, 4 • C, in a tabletop tissue culture centrifuge.
9b. Aspirate and discard the supernatant, and resuspend the cell pellet in 10 ml coculture medium. Akashi et al. (2000) and Pronk et al. (2007) .
Immortalize and passage the EB cells 10. Wash the irradiated producer cell monolayer (from step 1) once with 5 ml IMDM-ES-15 with glutamine and pen/strep.
11. Gently add the bone marrow or fetal liver cell suspension (∼3 × 10 5 cells/ml) to the irradiated cell monolayer. Incubate to coculture for 2 to 3 days, without changing the medium.
12. At the end of the coculture period, gently agitate the dishes to remove suspension cells loosely adherent to the monolayer and transfer the supernatant to a 15-ml conical tube.
13. Centrifuge 5 min at ∼200 × g, 4 • C.
14. Resuspend the cell pellet in 3 ml of immortalized cell medium and incubate in a 60-mm tissue culture dish. (Keller et al., 1998; Yu et al., 2002; Riz et al., 2007) .
Select for TLX1-expressing immortalized cells 16a. For cells transduced with the neo-carrying retrovirus cell line (GP+E-86/MSCV-HOX11):
Add Geneticin to a final concentration of 400 μg/ml.
16b. For cells transduced with the hyg-carrying retrovirus cell line (GP+E-86/MSCVhyg-HOX11):
Add hygromycin B to a final concentration of 400 μg/ml. (Yu et al., 2002; Su et al., 2006) 17. Clone Geneticin-or hygromycin B-resistant cells in methylcellulose as described in Support Protocol 2 or by limiting dilution in liquid culture (see Fuller et al., 2001 ) using immortalized cell medium containing the appropriate selective antibiotic.
While selection for retrovirally transduced cells with Geneticin or hygromycin B is recommended, it is not strictly required since TLX1-expressing cells will exhibit a growth advantage over nontransduced cells during in vitro passaging
The IL-3 containing methylcellulose and medium can be supplemented with other cytokines/growth factors such as SCF, Epo, etc. (Keller et al., 1998; Yu et al., 2002; Riz et al., 2007) .
18. Freeze clonal cell lines as described in Support Protocol 3.
19. Characterize the clonal lines, depending on the particular application, e.g., by identifying the hematopoietic cell lineage(s) represented, and their relative state of maturation (Support Protocol 4). 
MAINTENANCE OF TLX1 (HOX11) RETROVIRAL PRODUCER CELL LINES
The GP+E-86/MSCV-HOX11 producer cell line is a murine fibroblast cell line that exports helper-free replication-defective recombinant retrovirus carrying the TLX1 (HOX11) cDNA and the neo drug resistance gene (Hawley et al., 1994b) . The GP+E-86/MSCVhyg-HOX11 producer cell line is a murine fibroblast cell line that exports helper-free replication-defective recombinant retrovirus carrying for the TLX1 (HOX11) cDNA and the hyg drug resistance gene (Hawley et al., 1994b Fuller et al., 2001) in immortalized cell medium containing the appropriate selective antibiotic, depending on which TLX1 (HOX11) retroviral producer cell line was used for the immortalization (Geneticin for MSCV-HOX11 and hygromycin for MSCVhyg-HOX11). 3. Carefully aspirate off the supernatant, leaving a small amount (∼50 μl) of medium behind so as not to disturb the cell pellet.
CLONING OF IMMORTALIZED CELLS IN METHYLCELLULOSE
This protocol describes a method for cloning Geneticin-or hygromycin B-resistant immortalized cells in methylcellulose-based medium. Alternatively, the cells can be cloned by limiting dilution (see
Materials
4. Add 3.5 ml methylcellulose mix containing the appropriate selection antibiotic (Geneticin or hygromycin) to each tube, using a 5-ml syringe fitted with a 16-G needle. Carefully mix the cell-methylcellulose mixture by drawing it up and down in the syringe several times. Try to avoid making air bubbles.
5. Using the syringe and needle, add ∼1.5 ml of each of the mixtures into separate 35-mm dishes. Place six dishes in a 150-mm bacterial dish, including an extra uncovered 35-mm dish filled with sterile water at the center (to prevent drying out of the methylcellulose). Cover the 150-mm bacterial dish, and place it in the tissue culture incubator.
Examine the cultures daily.
Typically, colonies are large enough to pick after ∼1 week.
7. Choose dishes with well separated colonies. Under the inverted microscope, carefully aspirate selected colonies using a pipettor fitted with a disposable, sterile tip, and set at ∼10 μl. well. Be careful not to cross-contaminate neighboring wells when passing the pipettor over the plate.
Most of the colonies should grow nicely in the liquid culture.
9. Examine the cultures daily, and expand them to 1-ml cultures in 24-well plates once they are growing well.
10. Expand to progressively larger culture volumes as necessary, and/or freeze aliquots as described in Support Protocol 3.
SUPPORT PROTOCOL 3
CRYOPRESERVATION OF IMMORTALIZED CELLS
The following protocol describes a method we have found effective for cryopreservation of immortalized cells.
Materials
Suspension of immortalized cells (Basic Protocol, Alternate Protocol, or Support
Protocol 2) Immortalized cell medium (see recipe), ice cold 2× freezing medium (see recipe), ice cold Tissue culture centrifuge (refrigerated, benchtop centrifuge with swinging bucket rotor) 15-ml centrifuge tubes (sterile) 1.8-ml cryovials (Nunc, cat. no. 377267) −80
• C freezer Liquid nitrogen storage tank 1. Centrifuge 1 × 10 7 immortalized cells in 15-ml centrifuge tubes 5 min at 200 × g,
2. Aspirate and discard the supernatant, and resuspend the cells in 5 ml ice-cold immortalized cell medium.
3. Add 5 ml ice-cold 2× freezing medium. Pipet up and down to mix, and dispense 1-ml aliquots into each of 10 cryovials (∼1 × 10 6 cells/vial).
4. Cap vials and place on ice until they can be placed into a −80 • C freezer.
5. Incubate vials in a −80 • C freezer for 1 to 2 days, and then transfer to a liquid nitrogen tank for long-term storage.
This procedure can be scaled up to freeze more cells.
If there is poor viability after thawing, one can try substituting heat-inactivated fetal bovine serum (FBS) for the immortalized cell medium in step 2.
SUPPORT PROTOCOL 4
IMMUNOPHENOTYPIC ANALYSIS OF IMMORTALIZED CELL LINES BY FACS
Characterization of the clonal lines will depend on the particular application. However, identification of the hematopoietic cell lineages represented by the cell line, and their relative state of maturation, is common. A basic protocol for immunophenotypic analysis of hematopoietic lineage assignment by flow cytometry (FACS) and a list of suggested antibodies (Table 1F .7.1) are provided below. Additional procedures may include histochemical staining of the cells and/or reverse transcriptase-polymerase chain reaction (RT-PCR), northern blot analysis, or western blot analysis for lineage-specific and maturation specific gene expression. For a more detailed description and protocols pertaining to hematopoietic lineage analysis, see Baron (2005) . Table 1F . 
The stained cells can be stored for several hours at 4
• C before analyzing.
Analyze on a flow cytometer (FACS analyzer).
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REAGENTS AND SOLUTIONS
Ascorbic acid stock solution, 5 mg/ml
Prepare a stock solution of 5 mg L-ascorbic acid (Sigma; A-4544)/ml autoclaved water and sterilize by passing through a 0.22-μm filter. Prepare ascorbic acid stock solution fresh for each differentiation procedure.
Coculture medium
Fetal bovine serum, ES grade (FBS-ES; Hyclone), heat-inactivated (15%, v/v, final) 100× penicillin/streptomycin solution (Sigma; P4333): 1× (100 U penicillin/ml; 100 μg streptomycin/ml) final 200 mM glutamine (2 mM final) Interleukin-3 (IL-3; R & D Systems; 10 ng/ml final) Interleukin-6 (IL-6; R & D Systems; 2 ng/ml final) Interleukin-11 (IL-11; R & D Systems; 5 ng/ml final) Stem cell factor (SCF; R & D Systems; 50 ng/ml final) Isocove's modified Dulbecco's medium (IMDM; Invitrogen, cat. no. 12440) to make up the final volume Store up to 1 month at 4
• C
Heat inactivation of FBS is carried out for 30 min at 56
• C.
FACS wash buffer
10× phosphate-buffered saline, without calcium and magnesium (CMF-PB; Sigma, cat. no. P7059) diluted to 1× (final) with water Fetal bovine serum (FBS; Hyclone), heat-inactivated (1%, v/v, final) Sodium azide (0.1%, w/v, final) Store up to 6 months at 4
Heat inactivation of FBS is carried out for 30 min at 56
Freezing medium, 2×
Fetal bovine serum (FBS; Hyclone), heat-inactivated (60%, v/v, final) Dimethyl sulfoxide (DMSO; Sigma, cat. no. D8418; 20%, v/v, final) Immortalized cell medium (see recipe; 20%, v/v, final) Store indefinitely at −20 • C
Heat inactivation of FBS is carried out for 30 min at 56
The addition of DMSO to the solution is an exothermic reaction and will produce heat.
Cool the 2× freezing medium on ice before adding to cells for cryopreservation.
Gelatin 0.1% (w/v)
Dilute 10× phosphate-buffered saline without calcium and magnesium (CMF-PBS; Sigma, cat. no. P7059), to 1× with water. Sterilize by passing through a 0.22-μm filter. Add 0.5 g gelatin (Sigma, cat. no. G-1890) to 500 ml of the 1× CMF-PBS and autoclave. Store up to 1 month at 4 • C, in the absence of microbial contamination.
Gelatinized flasks
Prior to addition of ES cells, add enough 0.1% gelatin solution (see recipe) to coat the surface of the flask. Incubate at room temperature for 20 min. Remove excess gelatin solution before adding cells. Store up to 6 months at room temperature. 
IMDM-ES-5 with MTG and pen/strep
Fetal bovine serum, ES grade (FBS-ES; Hyclone), heat-inactivated (5%, v/v, final) α-monothioglycerol (MTG; Sigma, cat. no. M-1753; 12.4 μl/liter final) 100× penicillin/streptomycin solution (Sigma; P4333): 1× (100 U penicillin/ml; 100 μg streptomycin/ml) final Isocove's modified Dulbecco's medium (IMDM; Invitrogen, cat. no. 12440) to make up the final volume Store up to 1 month at 4
• C 
IMDM-ES-15 with glutamine and pen/strep
Fetal bovine serum, ES grade (FBS-ES; Hyclone), heat-inactivated (15%, v/v, final) 2 mM L-glutamine 100× penicillin/streptomycin solution (Sigma; P4333): 1× (100 U penicillin/ml; 100 μg streptomycin/ml) final Isocove's modified Dulbecco's medium (IMDM; Invitrogen, cat. no. 12440) to make up the final volume Store up to 2 months at 4
Heat inactivation of FBS is carried out for 30 min at 56
IMDM-ES-15 with MTG, LIF, and pen/strep
Fetal bovine serum, ES grade (FBS-ES; Hyclone), heat-inactivated (15%, v/v, final) α-monothioglycerol (MTG; Sigma, cat. no. M-1753; 12.4 μl/liter final; first diluted from stock, in IMDM, if necessary) Leukemia inhibitory factor (LIF; R & D Systems; 1000 U/ml final) 100× penicillin/streptomycin solution (Sigma; P4333): 1× (100 U penicillin/ml; 100 μg streptomycin/ml) final Isocove's modified Dulbecco's medium (IMDM; Invitrogen, cat. no. 12440) to make up the final volume Store up to 1 month at 4
Immortalized cell medium
Fetal bovine serum (FBS; standard tissue culture grade; Hyclone; heat-inactivated; 15%, v/v, final) 100× penicillin/streptomycin solution (Sigma; P4333): 1× (100 U penicillin/ml; 100 μg streptomycin/ml) final L-glutamine (2 mM final) Recombinant murine interleukin-3 (IL-3; R & D Systems, cat. no. 403-ML; 10 ng/ml final) or X630-recombinant IL-3-conditioned medium (Karasuyama and Melchers, 1988; 10%, v/v, 100× penicillin/streptomycin solution (Sigma; P4333): 1× (100 U penicillin/ml; 100 μg streptomycin/ml) final IL-3 (R & D systems, cat. no. 403-ML; 10 ng/ml final) Geneticin (Invitrogen, cat. no. 10131-035; 400 mg/ml final) or hygromycin B (400 mg/ml final) for selection (depending on the TLX1 retroviral producer cell line used for immortalization) Prepare fresh for each experiment
Prewarming the methylcellulose at 37
• C for a few minutes in a water bath makes it easier to work with.
Primary ES differentiation medium
1:1 fetal bovine serum (FBS; Hyclone), heat-inactivated/plasma-derived serum (PDS; Antech), 15% (v/v) final L-glutamine (2 mM final) α-monothioglycerol (MTG; 0.004%, v/v, final; first diluted from stock, in IMDM, if necessary) 5 mg/ml ascorbic acid stock solution (see recipe; 50 μg/ml final) Protein-free hybridoma medium (PFHMII; Invitrogen, cat. no. 23600-026; 5%, v/v, final) 100× penicillin/streptomycin solution (Sigma; P4333): 1× (100 U penicillin/ml; 100 μg streptomycin/ml) final IL-11 (5 ng/ml final) Recombinant murine or rat stem cell factor (rSCF; also called KL, kit-ligand; R & D Systems; 50 ng/ml final) Isocove's modified Dulbecco's medium (IMDM; Invitrogen, cat. no. 12440) to make up the final volume Store up to 1 month at 4
Heat inactivation of FBS is carried out for 30 min at 56
COMMENTARY
Background Information
The diverged homeobox-containing gene TLX1 (formerly called HOX11) was first identified in T cell acute lymphoblastic leukemia carrying the t(10;14)(q24;q11) chromosomal translocation (Dube et al., 1991; Hatano et al., 1991; Kennedy et al., 1991; Lu et al., 1991) . In this translocation, the T cell receptor δ chain gene regulatory sequences become juxtaposed to the 5 promoter region of the TLX1 gene, leading to aberrant TLX1 expression in the T cell lineage. A similar translocation, t(7;10)(q35;q24), places the T cell receptor β chain gene regulatory sequences into the TLX1 gene 5 promoter region, causing a similar effect. Subsequent studies showed that retroviral expression of TLX1 immortalizes murine hematopoietic cells derived from bone marrow cells, fetal liver, yolk sac, and in vitro differentiated ES cells at high frequency (Hawley et al., 1994a; Keller et al., 1998; Yu et al., 2002; Zhang et al., 2002; Yu et al., 2003; Owens et al., 2006) . A wide variety of hematopoietic cell types have been immortalized, including erythroid, megakaryocytic, myelocytic, and monocytic lineages. Interestingly, there are no reports of TLX1 immortalization of T lymphocyte progenitors, even though its misexpression disrupts T lymphocyte differentiation and leads to T cell leukemia in humans (Owens et al., 2006) . Essentially all of the reported TLX1-immortalized cell lines are IL-3 dependent for their growth and survival.
The mechanism of TLX1 cell immortalization remains incompletely understood. An intact homeodomain is required, suggesting direct transcriptional effects due to DNA binding activity (Owens et al., 2003) . However, overexpression of TLX1 deregulates genes involved in controlling G1/S cell cycle progression and disrupts a G2/M cell-cycle checkpoint, apparently by indirect mechanisms mediated in part via inhibition of PP1/PP2A phosphatase activity (Kawabe et al., 1997; Riz and Hawley, 2005) . TLX1 expression also alters the subcellular distribution of CREBbinding protein (CBP), a transcriptional coactivator with histone acetyltransferase activity (Riz et al., 2007) . It seems likely that multiple mechanisms contribute to TLX1 immortalization of hematopoietic progenitor cells. Examples of how TLX1 immortalized cell lines have been utilized experimentally include: (1) structure-function study of the GATA transcriptional cofactor Friend of GATA-1 (FOG-1; Cantor et al., 2002) ; (2) investigation of the role of the SHP-2 tyrosine phosphatase in interleukin-3 signaling (Yu et al., 2003) ; (3) chromatin immunoprecipitation assays demonstrating FOG-1 facilitation of GATA-1 chromatin occupancy (Pal et al., 2004) ; (4) establishment of a link between the proapoptotic BCL-2 family member Bid and the DNA-damage response (Zinkel et al., 2005) ; (5) testing the function of mitoferrin, a novel mitochondrial iron transporter (Shaw et al., 2006) ; and (6) transcription factor target gene identification using Cre-mediated excision in TLX1 immortalized cells generated from SCL flox/flox (H. Mikkola, pers. commun.) and Runx-1 flox/flox mice (M. Yu and A.B. Cantor, unpub. observ.) .
On a note of caution, the process of immortalization by TLX1 results in perturbed or arrested differentiation potential (Hawley et al., 1994a; Keller et al., 1998; Dixon et al., 2007; Riz et al., 2007) . This should be taken into consideration when designing cell fate experiments utilizing the TLX1 immortalized cell lines.
Critical Parameters and Troubleshooting
In our experience, the protocols for TLX1 immortalization of hematopoietic progenitors described in this unit yield cell lines quite readily. When using in vitro differentiated ES cells as a source of target cells, the time of EB harvest is an important consideration. We typically use EBs harvested at 7 days of culture. We have generated cell lines from 6-day-old EBs, but the efficiency seems to be lower. The stage of EB differentiation used for the immortalization will also theoretically affect whether primitive or definitive hematopoietic progenitors are targeted. We reported TLX1 immortalization of embryonic precursors with both primitive and definitive hematopoietic potential from day 7 EBs (Keller et al., 1998) . Two of the lines had the capacity to generate cells with both primitive and definitive erythroid potential. A third line was limited to definitive erythroid potential, but also had myeloid potential. We have also found that the quality and reproducibility of the ES cell in vitro differentiation declines when using older stock solutions of MTG. We therefore try to avoid using MTG stocks that are greater than 6 months old.
Most cells will continue to replicate after the coculture with TLX1 retroviral producer cells regardless of whether they are transduced by the TLX1 retroviruses. However, these nontransduced cells should eventually undergo senescence. Mast cells are particularly longlived and may be retained in primary cultures with IL-3 for many weeks before naturally senescing. Although one can "wait out" the eventual senescence of these nonimmortalized cells by serial passaging, one can also select for the TLX1-immortalized cells earlier by including Geneticin or hygromycin B (depending on the TLX1 retroviral vector used) in the medium beginning 48 hr after coculture with the retroviral producer cells. If not used up front, resistance to Geneticin or hygromycin B should be tested to ensure that the cells have been transduced with the retroviral vectors. In addition, immunoblot analysis of the final cell lines should be performed to ensure expression of TLX1. This migrates as an ∼37-kDa protein and can be detected using affinity-purified anti-TLX1 polyclonal antibody (HOX11 C18; Santa Cruz Biotechnology). Because immortalized hematopoietic cells typically grow in suspension, it is relatively easy to separate them from any residual retroviral producer cells, which are adherent; this is also easily accomplished by cloning in methylcellulose. However, the monolayer of producer cells can be irradiated with 3 Gy prior to adding the hematopoietic target cells to ensure that the producer cells do not contaminate future cell lines. Finally, MSCV-HOX11 retroviral producer cells can be eliminated by selection in Geneticin if the immortalized cell lines are derived from gene-targeted cells expressing the neo gene.
In our experience, TLX1-immortalized cells are strictly dependent on IL-3 for survival and growth. Therefore, it is critical to add IL-3 to the medium during the coculture with the retroviral producer cells, or at least soon after. We have used conditioned media from WEHI-3B cells (Lee et al., 1982) or X630-recombinant IL-3 cells (Karasuyama and Melchers, 1988) as a source of IL-3, but have found better cell growth and viability using recombinant murine IL-3 (10 ng/ml, R&D Systems).
Anticipated Results
After the 3-day coculture period, proliferation of the transferred suspension cells should be apparent within a few days, with cells
1F.7.17
growing as clusters in liquid medium. Even after cloning the cell lines, the wild-type cell cultures may remain heterogeneous with a mixture of self-renewing multipotent progenitor cells of various potentials, and differentiated progeny at various stages of maturation. Use of gene-targeted cells as the source of immortalized cells may lead to more homogenous cell populations if the disrupted gene is required for a specific stage of hematopoietic differentiation. For example, we generated a FOG-1 −/− cell line from in vitro differentiated FOG-1 −/− ES cells (Cantor et al., 2002; Fig. 1F.7.1) . This cell line is blocked in erythroid and megakaryocytic maturation (as expected), and therefore has a more homogenous morphology. Although genetic complementation of the cells by retrovirally expressed FOG-1 rescues the terminal maturation block, only about 35% of the cells differentiate in this case, as measured by staining with o-dianisidine for hemoglobin production. A large proportion of cells remain undifferentiated, presumably reflecting the self-renewing population of immortalized progenitor cells.
Time Considerations
Overall, generation of TLX1-immortalized cell lines can be accomplished within a couple of weeks. For the in vitro differentiation protocol, the ES cells are first differentiated for 7 days. The resultant EBs are then dissociated and directly cocultured on prepared TLX1 retroviral producer cell monolayers for 3 days. At this point, the transduced cells can be cultured as a pool, or cloned immediately in the presence of Geneticin or hygromycin B (and IL-3). Colonies should be detectable within about 2 weeks and expanded accordingly. Cell lines should be maintained by splitting at a dilution of ∼1:10-1:20 every 3 to 4 days. The doubling time of the cells may be in the range of ∼36 to 48 hr.
